PFE · NYSE · STOCK
Pfizer (PFE) Stock Analysis
$28.27
52W $23.62 – $29.21
53/100
$161.18B
37.4
0.28
Is PFE Bullish or Bearish?
Mixed.
Innellis AI committee rates Pfizer Inc. (PFE) Watch with a composite score of 53/100
, based on 5 analysts with 40% agreement.
Last updated October 10, 2026.
What Would Change This View
- Upgrade to Buy
- Requires a committee score of 60.0 — +6.98 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Reduce
- Requires the score to fall below 40.0 — -13.02 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Macro Analyst sees a compelling case. Portfolio Manager remains cautious — sector concentration is already high (hhi 2796.97). This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- Dividend yield of 5.4% pays you to wait — Value
- 5 consecutive earnings beats -- consistent execution — Growth
- Price structure making higher highs and higher lows — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- P/E of 36.9 is moderate-to-rich — Value
- ROE of only 4.9% -- cheap may mean cheap for a reason — Value
- Revenue declining -0.2% YoY -- this is not a growth story right now — Growth
- EPS declining -59.9% YoY despite any revenue growth — Growth
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
- MACD histogram negative -- bearish momentum — Technical
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of October 10, 2026
Overall Committee Score
53/100
Agreement
40%
Analysts
5
Conviction
Contested
Sector Rank
Top 80%
of 192 Healthcare peers
Value Analyst
neutral
42
/ 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
+ Dividend yield of 5.4% pays you to wait
− P/E of 36.9 is moderate-to-rich
Growth Analyst
bearish
38
/ 100 · High confidence
Growth story is weak, decelerating, or inconsistent
+ 5 consecutive earnings beats -- consistent execution
− Revenue declining -0.2% YoY -- this is not a growth story right now
Technical Analyst
bullish
61
/ 100 · High confidence
Price action is constructive -- trend and momentum agree
+ Price structure making higher highs and higher lows
− MACD histogram negative -- bearish momentum
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
neutral
60
/ 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
Portfolio Manager
bearish
30
/ 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2796.97)
Investment Thesis Evolution
Committee score moved marginally from 50.4 to 53.0.
- Conviction changed from moderate to contested.
- Committee agreement fell sharply from 60% to 40%.
- New bearish signals: 1 appeared.
- New bullish signals: 3 appeared.
- Bearish pressure eased: 1 signal(s) disappeared.
- Analyst(s) changed stance: Technical Analyst.
Analyst-level changes:
- Technical Analyst: stance neutral->bullish; score 48->61 (+13); +3 bullish signal(s).
- Value Analyst: +1 bearish signal(s).
Comparing 2026-10-09 to 2026-10-10 (1 day apart).
Technical Analysis
RSI (14)
57.6
Neutral
MACD Histogram
-0.068
Bearish Momentum
Trend Direction
Uptrend
Weekly: Uptrend
Market Structure
Hh Hl
Support
$27.86
Resistance
$28.73
Bollinger %B
0.66
Inside Bands
Price vs Moving Averages
EMA 9
$27.99
Above
EMA 21
$27.97
Above
EMA 50
$27.50
Above
EMA 200
$26.47
Above
Fundamental Analysis
Valuation
68
Growth
68
Profitability
54
Financial Health
63
Cash Flow
70
Valuation
P/E Ratio
37.4×
P/B Ratio
1.89×
PEG Ratio
-0.62
Dividend Yield
6.08%
52W High
$29.21
52W Low
$23.62
Quality & Growth
ROE
898.5%
ROA
373.3%
Gross Margin
7132.2%
Operating Margin
2508.2%
Revenue Growth YoY
—
Debt / Equity
0.74
AI Fundamental Assessment
P/E ratio of 37.4 (rich relative to a 15-40x range); Price-to-book of 1.9x; PEG ratio of -0.6 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 9.0%; Return on assets of 3.7%; Net margin of 6.8%; Gross margin of 71.3%; Current ratio of 1.27 (tight short-term liquidity); Debt-to-equity of 0.74; Free cash flow per share is positive (1.93); Most recent quarter beat estimates by 11.4%; 5 consecutive earnings beats; EPS growth decelerating (+13.6% -> +2.7% QoQ); Average YoY EPS growth of -1.3%; Analyst estimates rising over recent quarters
Get the Full PFE Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →